About | Free Trial

Last Update

2012-12-07T00:00:00.000Z

This profile was last updated on . .

Is this you? Claim your profile.

Background Information

Employment History

Norwegian Radium Hospital

Affiliations

Director
National Resource Centre for Long-Term Studies

Education

MD

Web References (18 Total References)


Testicular Cancer Resource Center's Testicular Cancer Experts List

tcrc.acor.org [cached]

Dr Sophie Fosså Section for Long Term Studies Professor Norwegian Radium Hospital, Montebello, Oslo, Norway Phone: +47 229 34000 Fax: +47 229 34593


Global Cancer Control Community - daily cancer news

www.uicc-community.org [cached]

Testicular cancer survivors face elevated mortality rates unrelated to their primary malignancy and higher risk of serious long-term effects, including cardiovascular morbidity and second cancers, according to Sophie D. Fosså, MD, of the Norwegian Radium Hospital at the University of Oslo, Norway, and colleagues. The study was reported in the November issue of British Journal of Urology International 2009; 104; 1418-22. Read more


'Health - Energy - Global Impact'

www.norway.org [cached]

4.00 Sophie D. Fosså, Director, National Resource Centre for Long-Term Studies after Cancer, The Norwegian Radium Hospital, Oslo: "The Cancer Survivorship Unit"

...
4.00 Sophie D. Fosså, Director, National Resource Centre for Long-Term Studies after Cancer, The Norwegian Radium Hospital, Oslo: "The Cancer Survivorship Unit"
...
4.00 Sophie D. Fosså, Director, National Resource Centre for Long-Term Studies after Cancer, The Norwegian Radium Hospital, Oslo: "The Cancer Survivorship Unit"
...
4.00 Sophie D. Fosså, Director, National Resource Centre for Long-Term Studies after Cancer, The Norwegian Radium Hospital, Oslo: "The Cancer Survivorship Unit"
...
4.00 Sophie D. Fosså, Director, National Resource Centre for Long-Term Studies after Cancer, The Norwegian Radium Hospital, Oslo: "The Cancer Survivorship Unit"


Dr. Sophie D. Fossa from ...

www.formkit.com [cached]

Dr. Sophie D. Fossa from Norwegian Radium Hospital in Oslo and colleagues compared prednisone (20 mg total daily dose) with flutamide (750 mg total daily dose) in the treatment of 201 men with symptomatic, metastatic hormone-resistant prostate cancer.They found that biochemical responses, times to progression, and overall survival did not differ between the two treatments.However, quality of life scores favored prednisone therapy, which brought significantly better relief of pain, nausea and vomiting, and diarrhea, as well as better role functioning (e.g., family, work, etc.) and less appetite loss.Flutamide therapy was associated with more gastrointestinal toxicity, but the side effects were otherwise similar between the treatments.The authors recommend that prednisone monotherapy be considered as a first-line, standard, hormonal manipulation of hormone-resistant prostate cancer, but the combination with tolerable cytotoxic treatment should be explored further.

*Journal of Clinical Oncology 2001;19:62-71


The Lancet Conferences: Asia Medical Forum 2007 - Asia and cancer management in the 21st century

www.hai.thelancetconferences.com [cached]

Prof Sophie Fossa

...
Prof Sophie Fossa Senior Clinical Scientist/Consultant, Department of Clinical Research, Section for Outcome Research, The Norwegian Radium Hospital, Norway

Similar Profiles

Other People with this Name

Other people with the name Fossa

Alexander Fossa
Amatis Networks Ltd

Kristina Fossa
UFP Technologies Inc

Arturo Pallete Fossa
Gloria S.A.

Roksana Fossa
United Technologies Corp.

Lisa Fossa
Cynosure Inc

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory